Walleye Capital
MDGL icon

Walleye Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Walleye Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$681K Buy
1,300
+700
+117% +$334K ﹤0.01% 2417
2025
Q4 		$349K Sell
600
-2,100
-78% -$1.07M ﹤0.01% 3193
2025
Q3 		$1.24M Buy
2,700
+2,300
+575% +$858K ﹤0.01% 1933
2025
Q2 		$121K Buy
400
+100
+33% +$29.8K ﹤0.01% 3677
2025
Q1 		$99.4K Buy
+300
New +$98.6K ﹤0.01% 3628
2024
Q3 		– Sell
-400
Closed -$112K – 5647
2024
Q2 		$112K Buy
400
+200
+100% +$47.6K ﹤0.01% 4661
2024
Q1 		$53.4K Buy
+200
New +$47.1K ﹤0.01% 4654
2023
Q2 		– Sell
-1,000
Closed -$242K – 4652
2023
Q1 		$242K Buy
+1,000
New +$272K ﹤0.01% 2307
2020
Q1 		– Sell
-900
Closed -$82K – 1372
2019
Q4 		$82K Buy
+900
New +$87.3K 0.01% 1407
2019
Q2 		– Sell
-5,400
Closed -$676K – 1916
2019
Q1 		$676K Buy
+5,400
New +$671K 0.11% 280

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Capital's MDGL Position: Q1 2026 in Review

Walleye Capital increased its Madrigal Pharmaceuticals (MDGL) stake by 19,070% in Q1 2026, buying an estimated $6.29M and bringing the position to 13,227 shares worth $6.92M. The position accounts for 0.03% of the portfolio, ranked #597.

Walleye Capital first reported a position in MDGL in Q4 2019 and has held it in 6 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Walleye Capital held 13,227 shares of Madrigal Pharmaceuticals worth $6.92M as of Q1 2026.
  • Walleye Capital bought 13,158 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $6.29M.
  • Madrigal Pharmaceuticals made up 0.03% of Walleye Capital's portfolio in Q1 2026, its #597 holding.
  • Walleye Capital first reported a position in Madrigal Pharmaceuticals in Q4 2019 and has held it in 6 quarters since.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.